App Arctic Mutation (App Arctic) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
App Arctic Mutation (App Arctic) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The APP Arctic mutation (E693G) is a pathogenic mutation in the amyloid precursor protein gene that causes familial Alzheimer's disease. Unlike other APP mutations that increase Aβ production, the Arctic mutation enhances Aβ aggregation and protofibril formation.
- Gene: APP (Amyloid Precursor Protein)
- Chromosome: 21q21.3
- Mutation: E693G (Glu693Gly)
- cDNA Change: c.2128A>G
- Discovery: 1998, Swedish family (Nordstedt et al.)
- Inheritance: Autosomal dominant
- Location: Within the Aβ sequence (Aβ position 22)
- Effect: Does NOT significantly increase total Aβ production
- Primary effect: Alters Aβ aggregation properties
- Production: Normal or slightly reduced
- Aggregation: Markedly accelerated
- Protofibrils: Increased formation of toxic Aβ protofibrils
- Oligomerization: Enhanced soluble oligomer formation
The Arctic mutation demonstrates that:
- Toxicity is not just about Aβ quantity
- Aβ aggregation kinetics are critical to pathogenesis
- Protofibrils and oligomers may be more toxic than plaques
This mutation was instrumental in shifting research focus toward Aβ oligomers as the true toxic species in AD.
- Typical onset: 55-70 years
- Similar to sporadic AD in timing
- Cognitive decline: Typical AD presentation
- Memory loss: Prominent early feature
- Progression: Similar rate to typical AD
- Plaques: Fewer dense-core plaques than other APP mutations
- Oligomers: High burden of soluble Aβ oligomers
- Vascular amyloid: Less severe than Flemish/Dutch mutations
- Anti-aggregation drugs: The Arctic mutation validates aggregation inhibitors
- Oligomer-targeting therapies: Antibodies against oligomers may be effective
- BACE inhibitors: May be less effective (production not increased)
- APP Arctic mice: Show cognitive deficits with minimal plaque deposition
- Demonstrate: Oligomer toxicity independent of plaque burden
App Arctic Mutation (App Arctic) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of App Arctic Mutation (App Arctic) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Nordstedt C, et al. (1998). The Arctic Alzheimer mutation produces an increased proportion of alpha- and reduced proportion of beta-amyloid peptides. Nature Genetics.
- Cheng IH, et al. (2007). Accelerating amyloid-beta fibrillization in vivo through mutation. Nature Neuroscience.
- Lord A, et al. (2006). An amyloid-beta protofibril-selective antibody prevents amyloid deposition in an Alzheimer disease mouse model. Journal of Clinical Investigation.